MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer
Authors:
- Marienid Flores-ColónMFMarienid Flores-Colón
- Mariela Rivera-SerranoMRMariela Rivera-Serrano
- Víctor G. Reyes-BurgosVRVíctor G. Reyes-Burgos
- José G. RolónJRJosé G. Rolón
- Josué Pérez-SantiagoJosué Pérez-Santiago
- María J. Marcos-MartínezMMMaría J. Marcos-Martínez
- Fatima ValiyevaFVFatima Valiyeva
- Pablo E. Vivas-MejíaPablo E. Vivas-Mejía
Open Access
- 28 March 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3793
Abstract
Metastasis and drug resistance are major contributors to cancer-related fatalities worldwide. In ovarian cancer (OC), a staggering 70% develop resistance to the front-line therapy, cisplatin. Despite proposed mechanisms, the molecular events driving cisplatin resistance remain unclear. Dysregulated microRNAs (miRNAs) play a role in OC initiation, progression, and chemoresistance, yet few studies have compared miRNA expression in OC samples and cell lines. This study aimed to identify key miRNAs involved in the cisplatin resistance of high-grade-serous-ovarian-cancer (HGSOC), the most common gynecological malignancy. MiRNA expression profiles were conducted on RNA isolated from formalin-fixed-paraffin-embedded human ovarian tumor samples and HGSOC cell lines. Nine miRNAs were identified in both sample types. Targeting these with oligonucleotide miRNA inhibitors (OMIs) reduced proliferation by more than 50% for miR-203a, miR-96-5p, miR-10a-5p, miR-141-3p, miR-200c-3p, miR-182-5p, miR-183-5p, and miR-1206. OMIs significantly reduced migration for miR-183-5p, miR-203a, miR-296-5p, and miR-1206. Molecular pathway analysis revealed that the nine miRNAs regulate pathways associated with proliferation, invasion, and chemoresistance through PTEN, ZEB1, FOXO1, and SNAI2. High expression of miR-1206, miR-10a-5p, miR-141-3p, and miR-96-5p correlated with poor prognosis in OC patients according to the KM plotter database. These nine miRNAs could be used as targets for therapy and as markers of cisplatin response.Keywords
Funding Information
- National Institutes of Health (5R16GM145558-02, 5R25GM061151-20, R25-GM061838, T32GM148406)
- National Institutes of Health (5R16GM145558-02, 5R25GM061151-20, R25-GM061838, T32GM148406)
This publication has 72 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Regulatory role of microRNAs in ovarian functionFertility and Sterility, 2014
- Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic markerBMC Cancer, 2014
- A p21-ZEB1 Complex Inhibits Epithelial-Mesenchymal Transition through the MicroRNA 183-96-182 ClusterMolecular and Cellular Biology, 2014
- The Role of MicroRNAs in Ovarian CancerBioMed Research International, 2014
- miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cellsOncogene, 2012
- MiR‐182 overexpression in tumourigenesis of high‐grade serous ovarian carcinomaThe Journal of Pathology, 2012
- miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress responseNature Medicine, 2011
- MicroRNA miR-183 Functions as an Oncogene by Targeting the Transcription FactorEGR1and Promoting Tumor Cell MigrationCancer Research, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009